Home  |  Contact

Cellosaurus HT-1376 (CVCL_1292)

[Text version]

Cell line name HT-1376
Synonyms HT1376; HT 1376; HT 1376.T
Accession CVCL_1292
Resource Identification Initiative To cite this cell line use: HT-1376 (RRID:CVCL_1292)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: UBC-40 urothelial bladder cancer cell line index.
Doubling time: 31 hours (PubMed=3708594); 31 hours (PubMed=26055179); ~60 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: HT-1367; In PubMed=29732388.
Sequence variations Homozygous for RB1 p.Gln702Ter (c.2104C>T) (PubMed=27270441).
TERT c.228C>T (-124C>T); in promoter (PubMed=24035680).
TP53 p.Pro250Leu (c.749C>T) (PubMed=7787250; PubMed=9850064).
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.48
Native American1.4
East Asian, North1.78
East Asian, South1.08
South Asian9.04
European, North26.62
European, South58.6
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RR15 (HT1376rCDDP1000)CVCL_RR16 (HT1376rGEMCI20)
Sex of cell Female
Age at sampling 58Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; KCLB; PubMed=11416159; PubMed=27270441

Markers:
AmelogeninX
CSF1PO12
D3S135814,17
D5S81811,12
D7S8209,12
D8S117914,16
D13S3179,11
D16S53911,14
D18S5114,15
D21S1126,32.2
FGA21,22
TH017,10 (ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=27270441)
7,9.3 (KCLB; PubMed=11416159)
TPOX8
vWA15,18

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/UC25
Publications

PubMed=191628; DOI=10.1093/jnci/58.4.881
Rasheed S., Gardner M.B., Rongey R.W., Nelson-Rees W.A., Arnstein P.
Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses.
J. Natl. Cancer Inst. 58:881-890(1977)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=7787250
Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J., Lippa M., Hatzivassiliou G., Tan J.
p53 mutations in bladder carcinoma cell lines.
Oncol. Res. 6:569-579(1994)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=24459064; DOI=10.1007/s13277-013-1604-3
Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Tumor Biol. 35:4599-4617(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ATCC; CRL-1472
ATCC; CRL-7927 - Discontinued
BCRC; 60058
DSMZ; ACC-397
ECACC; 87032402
IZSLER; BS TCL 70
KCLB; 21472
Cell line databases/resources CLDB; cl1743
CLDB; cl1744
CCLE; HT1376_URINARY_TRACT
Cell_Model_Passport; SIDM00678
Cosmic-CLP; 907066
GDSC; 907066
IGRhCellID; HT1376
LINCS_LDP; LCL-1712
Ontologies BTO; BTO:0003461
CLO; CLO_0004268
CLO; CLO_0004279
EFO; EFO_0002203
Biological sample resources BioSample; SAMN01821564
BioSample; SAMN01821635
BioSample; SAMN03472820
Chemistry resources ChEMBL-Cells; CHEMBL3308398
ChEMBL-Targets; CHEMBL612258
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM136230
GEO; GSM142305
GEO; GSM142310
GEO; GSM827432
GEO; GSM887139
GEO; GSM888210
GEO; GSM1374560
GEO; GSM1574553
GEO; GSM1669911
Other Wikidata; Q54896503
Polymorphism and mutation databases Cosmic; 715761
Cosmic; 760481
Cosmic; 845562
Cosmic; 907066
Cosmic; 925821
Cosmic; 928815
Cosmic; 943733
Cosmic; 1046691
Cosmic; 1285118
Cosmic; 1285987
Cosmic; 1927303
Cosmic; 2050444
Cosmic; 2057449
Cosmic; 2444252
Cosmic; 2686096
IARC_TP53; 3720
Entry history
Entry creation04-Apr-2012
Last entry updated24-May-2019
Version number28